A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 249 participants.
Also called NCT05450601
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 249 participants
- Registry
-
NCT05450601
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT05450601. Randomized; double masking; primary purpose treatment. Start 2022-09-01 (actual); primary completion 2023-12-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients
- Condition
- Hypertension
- Intervention (Drug)
- HCP2102-1
- Intervention (Drug)
- HPP2104-1
- Intervention (Drug)
- HCP2102-2
- Intervention (Drug)
- HPP2104-2
- Intervention (Drug)
- RLD2106-1
- Intervention (Drug)
- HPP2103-1
- Intervention (Drug)
- RLD2106-2
- Intervention (Drug)
- HPP2103-2
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
Record details
- Record id
cardio:ct-nct05450601- Content hash
dfa596838693cc3caf556f09748cb3e61217587186a0884bd5b8ae37e9ca923e